Results 221 to 230 of about 12,789,497 (387)

No Evidence for an Effect of the CCR5 Δ32/+ and CCR2b 64I/+ Mutations on Human Immunodeficiency Virus (HIV)‐1 Disease Progression among HIV‐1–Infected Injecting Drug Users [PDF]

, 1999
Janke Schinkel, Miranda Langendam, Roel A. Coutinho, Anneke Krol, Margreet Brouwer, Hanneke Schuitemaker   +5 more
openalex   +1 more source

Adenosine‐to‐inosine editing of miR‐200b‐3p is associated with the progression of high‐grade serous ovarian cancer

Molecular Oncology, EarlyView.
A‐to‐I editing of miRNAs, particularly miR‐200b‐3p, contributes to HGSOC progression by enhancing cancer cell proliferation, migration and 3D growth. The edited form is linked to poorer patient survival and the identification of novel molecular targets.
Magdalena Niemira, Anna Skwarska, Karolina Chwialkowska, Agnieszka Ostrowska, Gabriela Sokolowska, Anna Zeller, Anna Erol, Andrzej Eljaszewicz, Bartosz Hanczaruk, Anna Michalska‐Falkowska, Agnieszka Tarasik, Joanna Reszec‐Gielazyn, Pawel Knapp, Marcin Moniuszko, Adam Kretowski   +14 more
wiley   +1 more source

Critical Analysis of Markov Modeling for the Economic Evaluation of Obesity Interventions: A Systematic Review

Risk Management and Healthcare Policy
Qiucen Lin,1 Carolina Oi Lam Ung,1– 3 Yunfeng Lai,4 Hao Hu,1– 3 Mihajlo Jakovljevic5– 7 1State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, People’s Republic of China; 2Centre ...
Lin Q, Ung COL, Lai Y, Hu H, Jakovljevic M   +4 more
doaj  

LIFE's essential 8: a roadmap for preventing cardiometabolic disease progression. [PDF]

Nutr Metab (Lond)
Siervo M, Guan Z.
europepmc   +1 more source

Mechanisms of relapse in acute leukaemia: involvement of p53 mutated subclones in disease progression in acute lymphoblastic leukaemia [PDF]

, 1999
Y‐M Zhu, Letizia Foroni, I. Grant McQuaker, Mary Papaioannou, A. P. Haynes, Hanna Russell   +5 more
openalex   +1 more source

Investigating the cell of origin and novel molecular targets in Merkel cell carcinoma: a historic misnomer

Molecular Oncology, EarlyView.
This study indicates that Merkel cell carcinoma (MCC) does not originate from Merkel cells, and identifies gene, protein & cellular expression of immune‐linked and neuroendocrine markers in primary and metastatic Merkel cell carcinoma (MCC) tumor samples, linked to Merkel cell polyomavirus (MCPyV) status, with enrichment of B‐cell and other immune cell
Richie Jeremian, Sriraam Sivachandran, Melissa Galati, Brandon Ramchatesingh, Hibo Rijal, Johnny Hanna, Elena Netchiporouk, May Chergui, Margaret Redpath, Samy Abou Setah, Ivan V. Litvinov   +10 more
wiley   +1 more source

Smoking and the risk of prostate cancer: a review of risk and disease progression. [PDF]

Genes Environ
Sundaresan I, Palanisamy N, Saraswathy R.   +2 more
europepmc   +1 more source

Severe congenital neutropenia terminating in acute myeloid leukemia: Disease progression associated with mutations in the granulocyte-colony stimulating factor receptor gene [PDF]

, 1996
Ivo P. Touw, Fan Dong
openalex   +1 more source

The influence of ROS1 fusion partners and resistance mechanisms in ROS1‐TKI‐treated non‐small cell lung cancer patients

Molecular Oncology, EarlyView.
This real‐world study of ROS1+ NSCLC highlights fusion diversity, treatment outcomes with crizotinib and lorlatinib, and in vitro experiments with resistance mechanisms. G2032R drives strong resistance to ROS1‐targeted TKIs, especially lorlatinib. Fusion partner location does not affect overall survival to crizotinib or lorlatinib. Findings support the
Fenneke Zwierenga, Christa Dijkhuizen, Patrick Korthuis, Wim Timens, Harry Groen, Jeroen Hiltermann, Anke van den Berg, Lyndsay Drayer, Anthonie van der Wekken   +8 more
wiley   +1 more source

Splenic histiocytic sarcoma: Disease progression from the perspective of pathophysiology. [PDF]

World J Clin Cases
Yao MT, Wang T, Luo H, Yao MY, Chen K, Zhu YQ.   +5 more
europepmc   +1 more source